Clinical trial results:
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects with Chronic Hepatitis C Genotype 2, 4, 5 and 6 Infection

Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.

Summary

EudraCT number	2013-002169-21
Trial protocol	GB ES BE
Global end of trial date	04 December 2014

Results information

Result version number	v1 (current)
This version publication date	30 January 2016
First version publication date	30 January 2016

Trial information

Trial identification

Sponsor protocol code	5172-047

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01932762
WHO universal trial number (UTN)	-
Other trial identifiers	Merck Registration: MK-5172-047

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 December 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 December 2014
Global end of trial reached?	Yes
Global end of trial date	04 December 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of grazoprevir (MK-5172) used in combination with or without 50 mg of elbasvir (MK-8742) and/or RBV in treating non-cirrhotic treatment-naïve participants with chronic genotype (GT) 2, 4, 5, and 6 hepatitis C infection.

In Part A there is no randomization or stratification; all GT2 participants will be assigned to arm A1. In Part B, all GT2 participants will be assigned to Arm B1 and all participants with GT4, GT5 and GT6 will be randomized in a 1:1 ratio to either Arm 3 or Arm 4 with stratification by genotype.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 October 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 13
Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	Israel: 21
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	United States: 24
Worldwide total number of subjects	98
EEA total number of subjects	40

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	86
From 65 to 84 years	12
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

98 participants were assigned to treatment at 28 sites worldwide and all enrolled participants received ≥1 dose of study therapy. 30 participants enrolled in Part A and 68 were enrolled and randomized in Part B of the study. Enrollment in Part C, an evaluation of a fixed-dose combination of grazoprevir and elbasvir, was never initiated.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)

Arm description:

During Part A of the study, GT2 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of ribavirin (RBV) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg every day (QD) orally

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Rebetol®, Copegus®, Ribasphere®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant weight on Day 1

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

50 mg QD orally

Arm title	GT2: Grazoprevir + RBV (Arm B1)

Arm description:

During Part B of the study, GT2 participants received 100 mg grazoprevir plus standard weight-based dosing of RBV for 12 weeks.

Arm type	Experimental

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Rebetol®, Copegus®, Ribasphere®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant weight on Day 1

Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg every day (QD) orally

Arm title	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)

Arm description:

During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of RBV for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg every day (QD) orally

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

50 mg QD orally

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Rebetol®, Copegus®, Ribasphere®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant weight on Day 1

Arm title	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)

Arm description:

During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details: 50 mg QD orally	
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg every day (QD) orally

Number of subjects in period 1	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)
Started	30	30	19
Completed	24	28	19
Not completed	6	2	0
Consent withdrawn by subject	1	2	-
Physician decision	1	-	-
Lost to follow-up	4	-	-

Number of subjects in period 1	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Started	19
Completed	18
Not completed	1
Consent withdrawn by subject	-
Physician decision	-
Lost to follow-up	1

Baseline characteristics

Reporting groups	
Reporting group title	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)
Reporting group description:	
During Part A of the study, GT2 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of ribavirin (RBV) for 12 weeks.	
Reporting group title	GT2: Grazoprevir + RBV (Arm B1)
Reporting group description:	
During Part B of the study, GT2 participants received 100 mg grazoprevir plus standard weight-based dosing of RBV for 12 weeks.	
Reporting group title	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)
Reporting group description:	
During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of RBV for 12 weeks.	
Reporting group title	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Reporting group description:	
During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir for 12 weeks.	

Reporting group values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)
Number of subjects	30	30	19
Age categorical			
Units: Subjects			
Age Continuous |			
Units: years			
arithmetic mean	47.3	48.3	52.2
standard deviation	± 13.6	± 14.6	± 9.3
Gender, Male/Female			
Units: participants			
Female	11	13	11
Male	19	17	8

Reporting group values	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)	Total	
Number of subjects	19	98	
Age categorical			
Units: Subjects			
Age Continuous |			
Units: years			
arithmetic mean	52.8		
standard deviation	± 12.3	-	
Gender, Male/Female			
Units: participants			
Female	7	42	
Male	12	56	

End points

End points reporting groups

Reporting group title	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)
Reporting group description:	
During Part A of the study, GT2 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of ribavirin (RBV) for 12 weeks.	
Reporting group title	GT2: Grazoprevir + RBV (Arm B1)
Reporting group description:	
During Part B of the study, GT2 participants received 100 mg grazoprevir plus standard weight-based dosing of RBV for 12 weeks.	
Reporting group title	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)
Reporting group description:	
During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of RBV for 12 weeks.	
Reporting group title	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Reporting group description:	
During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir for 12 weeks.	

Primary: Percentage of Participants with Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)

End point title	Percentage of Participants with Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)[1]
End point description:	
SVR12 was defined as Hepatitis C Virus ribonucleic acid (HCV RNA) <25 IU/mL, either target detected but unquantifiable (TD[u]) or target not detected (TND), at 12 weeks after the end of all study therapy. The percentage of participants with SVR12 and accompanying 95% confidence intervals (CIs) were reported for each treatment arm in the Per-Protocol (PP) Population, which was composed of all randomized participants receiving ≥1 dose of study therapy with no important protocol deviations.	
End point type	Primary
End point timeframe:	
12 weeks after end of all therapy (Study Week 24)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There was no formal efficacy hypothesis testing planned for this endpoint, and there were no between-group statistical comparisons performed.

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27[2]	24[3]	17[4]	13[5]
Units: percentage of participants				
number (confidence interval 95%)	85.2 (66.3 to 95.8)	75 (53.3 to 90.2)	94.1 (71.3 to 99.9)	76.9 (46.2 to 95)

Notes:

[2] - All participants in the PP Population with available data.

[3] - All participants in the PP Population with available data.

[4] - All participants in the PP Population with available data.

[5] - All participants in the PP Population with available data.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Adverse Events (AEs), Serious AEs (SAEs), Drug-Related AEs, Drug-Related SAEs, or Discontinuation of Study Treatment Due to AE

End point title	Percentage of Participants with Adverse Events (AEs), Serious AEs (SAEs), Drug-Related AEs, Drug-Related SAEs, or Discontinuation of Study Treatment Due to AE[6]

End point description:

AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. An SAE was an AE that resulted in death, was life threatening, resulted in persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, was associated with an overdose, was another important medical event. Drug-related AEs were those determined by the investigator to be possibly, probably, or definitely related to the treatment

End point type	Primary

End point timeframe:

Treatment period plus the first 14 days of follow-up (up to 14 weeks)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There was no formal safety hypothesis testing planned for this endpoint, and there were no between-group statistical comparisons performed.

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	19	19
Units: percentage of participants				
number (confidence interval 95%)				
AEs	86.7 (69.3 to 96.2)	86.7 (69.3 to 96.2)	94.7 (74 to 99.9)	78.9 (54.4 to 93.9)
SAEs	3.3 (0.1 to 17.2)	3.3 (0.1 to 17.2)	0 (0 to 17.6)	0 (0 to 17.6)
Drug-related AE	63.3 (43.9 to 80.1)	63.3 (43.9 to 80.1)	57.9 (33.5 to 79.7)	36.8 (16.3 to 61.6)
Drug-related SAE	0 (0 to 11.6)	3.3 (0.1 to 17.2)	0 (0 to 17.6)	0 (0 to 17.6)
Discontinuation due to AE	0 (0 to 11.6)	0 (0 to 11.6)	0 (0 to 17.6)	5.3 (0.1 to 26)

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Time to First Achievement of Undetectable HCV RNA During Treatment

End point title	Mean Time to First Achievement of Undetectable HCV RNA During Treatment

End point description:

HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at TWs 1, 2, 4, 8, and 12. Undetectable HCV RNA (or TND) was defined as below the 9.3 IU/ml limit of detection. Kaplan Meier summary statistics were calculated for each treatment arm in the Full Analysis Set (FAS).

End point type	Secondary

End point timeframe:

From TW1 until first achievement of undetectable HCV RNA (up to 12 weeks)

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30[7]	26[8]	19[9]	18[10]
Units: days				
arithmetic mean (standard error)	25.2 (± 2.8)	26.9 (± 3)	27.4 (± 4.5)	21.3 (± 1.7)

Notes:

[7] - Participants in the FAS not achieving TND were censored from the analysis.

[8] - Participants in the FAS not achieving TND were censored from the analysis.

[9] - Participants in the FAS not achieving TND were censored from the analysis.

[10] - Participants in the FAS not achieving TND were censored from the analysis.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving Undetectable HCV RNA During Treatment By Timepoint

End point title	Percentage of Participants Achieving Undetectable HCV RNA During Treatment By Timepoint

End point description:

HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at TWs 1, 2, 4, 8, and 12. Undetectable HCV RNA (or TND) was defined as below the 9.3 IU/ml limit of detection. The percentage of participants achieving undetectable HCV RNA and accompanying 95% CIs were reported at TW2, TW4, and TW12 for each treatment arm of the PP Population.

End point type	Secondary

End point timeframe:

From TW 2 through TW 12 (up to 12 weeks)

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28[11]	24[12]	17[13]	15[14]
Units: percentage of participants				
number (confidence interval 95%)				
Week 2 (n=28, 24, 16, 15)	42.9 (24.5 to 62.8)	50 (29.1 to 70.9)	50 (24.7 to 75.3)	53.3 (26.6 to 78.7)
Week 4 (n=28, 24, 17, 15)	85.7 (67.3 to 96)	79.2 (57.8 to 92.9)	88.2 (63.6 to 98.5)	80 (51.9 to 95.7)
Week 12 (n=28, 24, 17, 14)	96.4 (81.7 to 99.9)	83.3 (62.6 to 95.3)	100 (80.5 to 100)	78.6 (49.2 to 95.3)

Notes:

[11] - All participants in the PP Population with available data.

[12] - All participants in the PP Population with available data.

[13] - All participants in the PP Population with available data.

[14] - All participants in the PP Population with available data.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving HCV RNA <25 IU/mL During Treatment By Timepoint

End point title	Percentage of Participants Achieving HCV RNA <25 IU/mL During Treatment By Timepoint

End point description:

HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at TWs 1, 2, 4, 8, and 12. The Roche COBAS™ Taqman™ HCV Test (v.2.0) has a lower limit of quantification (LLoQ) of 25 IU/ml and a limit of detection of 9.3 IU/ml. The percentage of participants with HCV RNA levels <25 IU/ml (either TD[u] or TND) and accompanying 95% CIs were reported at TW2, TW4, and TW12 for each treatment arm of the PP Population.

End point type	Secondary

End point timeframe:

From TW 2 through TW 12 (up to 12 weeks)

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28[15]	24[16]	17[17]	15[18]
Units: percentage of participants				
number (confidence interval 95%)				
Week 2 (n=28, 24, 16, 15)	96.4 (81.7 to 99.9)	79.2 (57.8 to 92.9)	87.5 (61.7 to 98.4)	93.3 (68.1 to 99.8)
Week 4 (n=28, 24, 17, 15)	100 (87.7 to 100)	91.7 (73 to 99)	100 (80.5 to 100)	93.3 (68.1 to 99.8)
Week 12 (n=28, 24, 17, 14)	96.4 (81.7 to 99.9)	87.5 (67.6 to 97.3)	100 (80.5 to 100)	85.7 (57.2 to 98.2)

Notes:

[15] - All participants in the PP Population with available data.

[16] - All participants in the PP Population with available data.

[17] - All participants in the PP Population with available data.

[18] - All participants in the PP Population with available data.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving SVR4

End point title	Percentage of Participants Achieving SVR4

End point description:

SVR4 was defined as HCV RNA <25 IU/mL, either TD(u) or TND, at 4 weeks after the end of all study therapy. The percentage of participants with SVR4 and accompanying 95% CIs were reported for each treatment arm of the PP Population.

End point type	Secondary

End point timeframe:

4 weeks after end of all therapy (Study Week 16)

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27[19]	24[20]	17[21]	14[22]
Units: percentage of participants				
number (confidence interval 95%)	88.9 (70.8 to 97.6)	83.3 (62.6 to 95.3)	94.1 (71.3 to 99.9)	78.6 (49.2 to 95.3)

Notes:

[19] - All participants in the PP Population with available data.

[20] - All participants in the PP Population with available data.

[21] - All participants in the PP Population with available data.

[22] - All participants in the PP Population with available data.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving SVR24

End point title	Percentage of Participants Achieving SVR24

End point description:

SVR24 was defined as HCV RNA <25 IU/mL, either TD(u) or TND, at 24 weeks after the end of all study therapy. The percentage of participants with SVR24 and accompanying 95% CIs were reported for each treatment arm of the PP Population.

End point type	Secondary

End point timeframe:

24 weeks after end of all therapy (Study Week 36)

End point values	GT2: Grazoprevir + Elbasvir + RBV (Arm A1)	GT2: Grazoprevir + RBV (Arm B1)	GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)	GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26[23]	24[24]	17[25]	13[26]
Units: percentage of participants				
number (confidence interval 95%)	84.6 (65.1 to 95.6)	75 (53.3 to 90.2)	94.1 (71.3 to 99.9)	76.9 (46.2 to 95)

Notes:

[23] - All participants in the PP Population with available data.

[24] - All participants in the PP Population with available data.

[25] - All participants in the PP Population with available data.

[26] - All participants in the PP Population with available data.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Treatment Week (TW) 1 through Follow-Up Week (FW) 24 (up to 36 weeks)

Adverse event reporting additional description:

AEs were reported for the ASAT Population (all randomized participants who received ≥ 1 dose of study therapy) for both the treatment and follow-up periods.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.1

Reporting groups

Reporting group title	GT2: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm A1)

Reporting group description:

During Part A of the study, GT2 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of RBV for 12 weeks.

Reporting group title	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm B2)

Reporting group description:

During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir plus standard weight-based dosing of RBV for 12 weeks.

Reporting group title	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg (Arm B3)

Reporting group description:

During Part B of the study, GT4/GT5/GT6 participants received 100 mg grazoprevir plus 50 mg elbasvir for 12 weeks.

Reporting group title	GT2: MK-5172 100 mg + RBV (Arm B1)

Reporting group description:

During Part B of the study, GT2 participants received 100 mg grazoprevir plus standard weight-based dosing of RBV for 12 weeks.

Serious adverse events	GT2: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm A1)	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm B2)	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg (Arm B3)
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	0 / 19 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure acute			

subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GT2: MK-5172 100 mg + RBV (Arm B1)		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 30 (3.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	GT2: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm A1)	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg + RBV (Arm B2)	GT4,5,6: MK-5172 100 mg + MK-8742 50 mg (Arm B3)
Total subjects affected by non-serious adverse events			

subjects affected / exposed	26 / 30 (86.67%)	18 / 19 (94.74%)	15 / 19 (78.95%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenoma benign			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Hypotension			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	5 / 30 (16.67%)	3 / 19 (15.79%)	4 / 19 (21.05%)
occurrences (all)	5	3	4
Chest pain			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Fatigue			
subjects affected / exposed	12 / 30 (40.00%)	5 / 19 (26.32%)	3 / 19 (15.79%)
occurrences (all)	13	5	3
Feeling cold			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 19 (0.00%)	2 / 19 (10.53%)
occurrences (all)	2	0	2
Thirst			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Genital tract inflammation			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	5 / 30 (16.67%)	4 / 19 (21.05%)	4 / 19 (21.05%)
occurrences (all)	5	4	5
Dyspnoea			
subjects affected / exposed	4 / 30 (13.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	4	1	0
Dyspnoea exertional			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	3 / 19 (15.79%)
occurrences (all)	1	0	3
Rhinorrhoea			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	2 / 30 (6.67%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	2	0	1
Depression			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	2 / 30 (6.67%)	3 / 19 (15.79%)	2 / 19 (10.53%)
occurrences (all)	3	3	3
Irritability			
subjects affected / exposed	3 / 30 (10.00%)	1 / 19 (5.26%)	1 / 19 (5.26%)
occurrences (all)	3	1	1
Sleep disorder			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Investigations			

Alanine aminotransferase increased			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	2 / 19 (10.53%)
occurrences (all)	0	0	2
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Blood bilirubin increased			
subjects affected / exposed	2 / 30 (6.67%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	4 / 30 (13.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	7	1	0
Foot fracture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Inflammation of wound			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Nervous system disorders			
Disturbance in attention			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Dizziness			
subjects affected / exposed	7 / 30 (23.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	8	0	2
Dysgeusia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Headache			
subjects affected / exposed	6 / 30 (20.00%)	6 / 19 (31.58%)	5 / 19 (26.32%)
occurrences (all)	8	8	20

Hypoaesthesia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Lethargy			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Memory impairment			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Poor quality sleep			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Somnolence			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 30 (13.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	5	1	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Abdominal pain			
subjects affected / exposed	1 / 30 (3.33%)	2 / 19 (10.53%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Abdominal pain upper			
subjects affected / exposed	2 / 30 (6.67%)	0 / 19 (0.00%)	2 / 19 (10.53%)
occurrences (all)	3	0	2
Abdominal tenderness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	3 / 30 (10.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	3	0	1
Diarrhoea			

subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	4 / 19 (21.05%)
occurrences (all)	1	1	4
Dry mouth			
subjects affected / exposed	2 / 30 (6.67%)	3 / 19 (15.79%)	1 / 19 (5.26%)
occurrences (all)	2	3	1
Dyspepsia			
subjects affected / exposed	2 / 30 (6.67%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
Enteritis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Faeces pale			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Haemorrhoids			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	2 / 19 (10.53%)
occurrences (all)	0	0	2
Lip dry			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	5 / 30 (16.67%)	2 / 19 (10.53%)	1 / 19 (5.26%)
occurrences (all)	5	3	1
Stomatitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	3
Vomiting			
subjects affected / exposed	5 / 30 (16.67%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	6	0	1
Hepatobiliary disorders			

Hepatomegaly			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	3 / 30 (10.00%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Dry skin			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Eczema			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	2
Pruritus			
subjects affected / exposed	2 / 30 (6.67%)	2 / 19 (10.53%)	1 / 19 (5.26%)
occurrences (all)	3	3	2
Rash			
subjects affected / exposed	2 / 30 (6.67%)	3 / 19 (15.79%)	0 / 19 (0.00%)
occurrences (all)	2	5	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	3 / 19 (15.79%)
occurrences (all)	1	1	9
Back pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	2 / 19 (10.53%)
occurrences (all)	0	1	3
Bone pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Flank pain			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1

Joint swelling			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Muscle contracture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	2 / 19 (10.53%)
occurrences (all)	1	0	2
Pain in extremity			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Influenza			
subjects affected / exposed	3 / 30 (10.00%)	0 / 19 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Laryngitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Oral herpes			
subjects affected / exposed	1 / 30 (3.33%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Rhinitis			

subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 19 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Viral infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 30 (3.33%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Dyslipidaemia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 19 (5.26%)	0 / 19 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	GT2: MK-5172 100 mg + RBV (Arm B1)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 30 (83.33%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenoma benign			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Hypotension			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 30 (20.00%)		
occurrences (all)	6		
Chest pain			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	6 / 30 (20.00%)		
occurrences (all)	7		
Feeling cold			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Influenza like illness			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Thirst			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Reproductive system and breast disorders			
Genital tract inflammation			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Dyspnoea			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Dyspnoea exertional			

subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	2		
Rhinorrhoea			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Irritability			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Sleep disorder			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			

Accidental overdose			
subjects affected / exposed	4 / 30 (13.33%)		
occurrences (all)	6		
Foot fracture			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Inflammation of wound			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Disturbance in attention			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	2		
Dysgeusia			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	4 / 30 (13.33%)		
occurrences (all)	5		
Hypoaesthesia			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Memory impairment			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Poor quality sleep			

subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Abdominal tenderness			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	2		
Dry mouth			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Dyspepsia			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Enteritis			

subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Faeces pale			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Haemorrhoids			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Lip dry			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Mouth ulceration			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	4 / 30 (13.33%)		
occurrences (all)	6		
Stomatitis			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	3		
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Dry skin			

subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Eczema			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 30 (10.00%)		
occurrences (all)	4		
Back pain			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Bone pain			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Flank pain			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Joint swelling			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Muscle contracture			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			

subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	1 / 30 (3.33%)		
occurrences (all)	1		
Laryngitis			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Oral herpes			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	2 / 30 (6.67%)		
occurrences (all)	2		
Sinusitis			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	0 / 30 (0.00%)		
occurrences (all)	0		

Urinary tract infection subjects affected / exposed occurrences (all) Viral infection subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0 0 / 30 (0.00%) 0		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) Dyslipidaemia subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2 0 / 30 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 September 2013	Protocol amendment 1 (AM1) included changes to the inclusion and exclusion criteria, added electrocardiographs to TW 4 and TW12 visits, and added collection of vital signs to every visit.
14 October 2013	AM2 revised the study design to add Part B (included 3 additional arms for treating participants with genotypes 4, 5, and 6 infection), revised the study objectives, hypotheses, and statistical analysis plan to include Part B, and added Part B-specific eligibility and early trial termination criteria.
08 May 2014	AM3 revised the study design to add Part C, revised the study objectives, hypotheses, and statistical analysis plan to include Part C and added a primary hypothesis for Part C, added Part C-specific eligibility criteria and added new early trial termination criteria for Part B.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported